Through major licensing agreements with Ayrmid ($10M upfront + $87M potential milestones) and GloriaBio ($15M upfront + $250M potential milestones), BioLineRx secures non-dilutive capital. The ongoing CheMo4METPANC Phase 2b clinical trial of motixafortide in metastatic pancreatic cancer is led by Columbia University and supported by both Regeneron and BioLineRx. BioLineRx also established a joint venture with Hemispherian to develop GLIX1, a Phase 1-ready candidate for glioblastoma, a >$3.7 billion global addressable market.
Cyborg Score Rationale
With $25.2M on its balance sheet as of September 30, 2025, BioLineRx is maintaining its cash runway guidance into the first half of 2027. The company benefits from non-dilutive partnerships and retained oncology IP, but faces execution risk on pipeline programs and limited commercial revenue generation to date.
Top Insights
The combination of non-dilutive funding, equity investments from partners and potential royalty streams creates multiple paths to value creation.
Phase 1/2a clinical trial of GLIX1 is expected to commence in Q1 2026 with world-leading investigators Dr. Roger Stupp and Dr. Ditte Primdahl as principal investigators.
GLIX1 patent protection extends to 2040 with possible 5-year extension, covering >90% of cancer cases.
Company implemented 1-for-40 reverse stock split effective January 30, 2025, to maintain Nasdaq compliance.
Named Competitors
Stem cell mobilization for hematologic cancers — FDA-approved CXCR4 antagonist for stem cell mobilization
DNA damage response inhibitors — Cancer immunotherapy and DDR combination approaches
Glioblastoma therapeutics — Tumor-targeted immunotherapies for glioblastoma
Recent Developments
(November 2025) Phase 1/2a GLIX1 glioblastoma trial preparation advanced; patent allowance strengthens IP protection to 2040
(September 2025) Joint venture established with Hemispherian for GLIX1 cancer therapeutic development
(January 2025) Major licensing deals with Ayrmid and GloriaBio secure $25M upfront capital; cash runway extended to H1 2027
Open the full interactive BioLineRx Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.